SCHEMBL4699558

SCHEMBL4699558

CC(C)(C)OC(=O)N1CCN(c2ccc(-c3nocc3NC(=O)OCC(Cl)(Cl)Cl)cc2)CC1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 5/20 0.44
MAPT P10636 4/20 0.44
MEN1 O00255 3/20 0.44
KMT2A Q03164 3/20 0.44
TSHR P16473 1/20 0.44
ALOX5 P09917 1/20 0.43
HTT P42858 2/20 0.42
NPSR1 Q6W5P4 1/20 0.42
LMNA P02545 3/20 0.42
ALDH1A1 P00352 2/20 0.42
NAMPT P43490 1/20 0.42
ESR2 Q92731 1/20 0.41
NPC1 O15118 1/20 0.41
NR2F2 P24468 1/20 0.41
CYP2C19 P33261 1/20 0.41
CCNK O75909 1/20 0.40
CCNA2 P20248 1/20 0.40
CDK2 P24941 1/20 0.40
CCND3 P30281 1/20 0.40
CDK9 P50750 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4702061 0.85 SMN1; SMN2 (0.45) SMN1; SMN2MAPTMEN1KMT2ATSHR
SCHEMBL4698621 0.83 MAPKAPK2 (0.42) ALDH1A1
SCHEMBL4699272 0.80 SMN1; SMN2 (0.46) SMN1; SMN2MAPTMEN1KMT2ATSHR
SCHEMBL4701596 0.77 CTSS (0.42) SMN1; SMN2MAPTMEN1KMT2ATSHR
SCHEMBL4699782 0.77 CTSS (0.49) SMN1; SMN2MAPTMEN1KMT2ATSHR
SCHEMBL4699780 0.77 CTSS (0.49) SMN1; SMN2MAPTMEN1KMT2ATSHR
SCHEMBL4699058 0.77 MAPT (0.49) SMN1; SMN2MAPTMEN1KMT2ATSHR
SCHEMBL4700415 0.76 MAPT (0.51) SMN1; SMN2MAPTMEN1KMT2ATSHR
SCHEMBL4704295 0.76 ALOX5 (0.43) SMN1; SMN2MAPTMEN1KMT2ATSHR
SCHEMBL4701890 0.72 CTSS (0.60) CTSSCTSK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1372655-B1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS MERCK FROSST CANADA LTD (CA) 2008-10-01 EP disclosed
US-7012075-B2 Cathepsin cysteine protease inhibitors MERCK & CO., INC. (US) 2006-03-14 US disclosed
EP-1372655-A4 CATHEPSIN CYSTEINE PROTEASE INHIBITORS MERCK FROSST CANADA INC (CA) 2005-10-12 EP disclosed
US-20040198982-A1 Cathepsin cysteine protease inhibitors MERCK CANADA INC. (CA) 2004-10-07 US disclosed
EP-1372655-A2 CATHEPSIN CYSTEINE PROTEASE INHIBITORS Merck Frosst Canada & Co. (CA) 2004-01-02 EP disclosed
WO-2002069901-A2 CATHEPSIN CYSTEINE PROTEASE INHIBITORS MERCK FROSST CANADA & CO. (CA) 2002-09-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040198982-A1 Cathepsin cysteine protease inhibitors CTSB, CTSS, CTSZ SMN1; SMN2 4512/4885MAPT 3191/4885MEN1 3555/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.